Expedition Therapeutics

“Expedition Therapeutics Closes $115 Million Series B.”

“Large biotech rounds (Vedanta, Expedition Therapeutics at $115M) signal continued LP appetite for long-cycle science bets running parallel to the AI wave.”

“Expedition Therapeutics, an SF-based developer of oral therapies for inflammatory and respiratory diseases, raised $115m in Series B funding led by General Atlantic with a broad institutional syndicate.”